Reports of PI3K/mTOR activation in multiple childhood cancers led the PPTP/C to evaluate 9 inhibitors in this pathway against both solid tumors and ALL, including: PI3K inhibitors (pilaralisib [SAR245408, XL147] (Reynolds et al., 2013), voxtalisib [XL765], copanlisib and duvelisib), AKT inhibitors [GSK690693 (Carol et al., 2010) and MK2206 (Gorlick et al., 2012)]; mTORC1/2 inhibitors [AZD8055 (Houghton et al., 2012) and sapanisertib (MLN0128, TAK-228) (Kang et al., 2014)]; and a mTORC1-specific inhibitor [rapamycin (Houghton et al., 2008)]. Here, MTOR is linked to acute lymphoblastic leukemia.